New triple-hormone drug shows unprecedented weight loss for diabetics
Retatrutide trial demonstrates 25% body weight reduction while controlling blood sugar
1Breakthrough in diabetes care
Eli Lilly's experimental drug retatrutide achieved up to 25% body weight reduction in type 2 diabetes patients during clinical trials. Unlike existing GLP-1 drugs targeting one or two hormones, retatrutide mimics three hormones simultaneously to control appetite, blood sugar, and metabolism. The 80-week study across 92 sites involved over 2,000 participants with BMI over 27, comparing different doses against placebo.
2Dose-dependent results
Patients receiving 4mg of retatrutide lost 11.9% body weight on average, increasing to 16.8% with 9mg and 18.8% with 12mg. The placebo group averaged 5.1% loss. At maximum dose, 47% lost ≥20% weight and 31% lost ≥25%, versus 6% and 3% respectively with placebo. Nearly three-quarters achieved diabetes remission thresholds (HbA1c ≤6.5%) compared to 29% on placebo.
3Safety profile assessment
Primary side effects were gastrointestinal (diarrhea, nausea), with seven deaths occurring across all groups - deemed unrelated to treatment. Researchers noted the safety profile resembled other GLP-1 agonists. The trial suggests retatrutide could overcome historical challenges in achieving weight loss for diabetics while improving cardiometabolic risk factors, though longer-term studies are needed.
4Comparative mechanism advantage
Retatrutide's triple-hormone action (GLP-1, GIP, glucagon receptor agonism) differentiates it from single/dual-hormone competitors. This multi-target approach appears more effective for both weight loss and glycemic control in diabetic populations. Researchers propose obesity treatment itself as a viable strategy for diabetes management when using such comprehensive metabolic regulators.
5Parallel amylin-based therapy
A separate EASD-presented trial tested petrelintide, an amylin-mimicking drug achieving >10% weight loss with fewer side effects. Involving 485 participants across 32 sites, this weekly injection could benefit patients intolerant to GLP-1 medications. Researchers highlight amylin therapies may improve treatment adherence through better tolerability while still delivering significant weight reduction.
6Clinical implications
The findings challenge current diabetes management paradigms by demonstrating substantial weight loss is achievable alongside glycemic control. Retatrutide's results suggest obesity treatment could become central to diabetes care rather than secondary. However, researchers caution these benefits need confirmation regarding long-term outcomes and obesity-related complications.
7Regulatory pathway
While showing promise, retatrutide hasn't received UK approval yet. The Lancet publication and EASD presentation aim to build clinical consensus. Researchers emphasize need for further studies to confirm whether metabolic improvements translate to reduced cardiovascular risks and other diabetes complications - key factors for regulatory evaluation and treatment guidelines.
8Treatment landscape shift
These trials signal a potential transformation in obesity-diabetes therapeutics, moving beyond glucose management to comprehensive metabolic regulation. The dual success of hormone-mimicking approaches (retatrutide's triple action and petrelintide's amylin focus) suggests multiple pharmacological pathways may soon expand treatment options for this high-need population.